Late-Breaking Research: Clinical Research 3

• LB320 · PDF 癌症与阿尔茨海默病之间的反向关系：自噬与凋亡信号机制之间的重要相互作用 Inverse relationship between cancer and Alzheimer's disease: Important interplay between autophagy and apoptosis signaling mechanisms Jagadeesh Narasimhappagari, Meenakshisundaram Balasubramaniam, Srinivas Ayyadevara, W Sue T Griffin
• LB322 · PDF 靶向衰老以逆转乳腺癌幸存者化疗诱导的肌肉老化：TROFFi试验的一项辅助研究 Targeting senescence to reverse chemotherapy-induced muscle aging in breast cancer survivors: An ancillary study of the TROFFi Trial Yuliya Zektser, Catherine Crespi, Sam Margolis, Arman Niknafs, Jingran Ji, Nikita Baclig, Mina Sedrak
• LB324 · PDF Community Living Lab学习型健康系统对黑人男性前列腺癌知识、态度、信念和行动线索的影响 The impact of the Community Living Lab learning health system on the prostate cancer knowledge, attitudes, beliefs, and cues to action of Black men Folakemi T. Odedina, Opeyemi Oreoluwa Bolajoko, Quincy A. Wimberly, Daniel W. Lee, Floyd B. Willis, Toshiko Moultrie, Wayne Ford, Derry Green, Arnold J. Merriweather, Michelle Fudge
• LB325 LB325 修订日本保险制度与患者倡导活动 Revising Japan's insurance system and patient advocacy activities Naomi Sakurai, Shinsuke Amano, Hiromi Todoroki, Yoko Matsumoto, Yoshiyuki Majima, Maiko Higuchi, Mina Katome, Ruri Kobayashi, Ayako Yago, Yuka Tsujimoto, Yuri Ito
• LB326 · PDF 即时制备的PRAME特异性TCR-T细胞疗法在一例接受过多线重度预处理、患有广泛多灶性肾母细胞瘤的儿科患者中诱导深度缓解 Point-of-care-manufactured PRAME-specific TCR T cell therapy induces deep remission in a heavily pre-treated pediatric patient with extensive, multifocal nephroblastoma Katharina Mair, Corinne Rossi, Jens H. Westhoff, Esther Wahlbrink, Kendra Maass, Sophia Scheuermann, Fabienne Engelmann, Simon Krost, Alexandra Tuch, Barbara Jones, Laura Fankhauser, Joachim B. Kunz, Johann Greil, Stella Okouoyo, Florian Selt, Elke Pfaff, Jutta Mattern, Maria E. Kögler, Roland Imle, Abdulsattar Alrajab, Jens-Peter Schenk, Inga Harting, Erik Winter, Patrick Günther, Markus Keßler, Astrid Burger, Juri Fuchs, Anita Schmitt, Carsten Müller-Tidow, Kathrin Schramm, Stefanie Volz, Robert J. Autry, David T. W. Jones, Kristian W. Pajtler, Dirk Jäger, Stefan Pfister, Thomas Grünewald, Andreas E. Kulozik, Olaf Witt, Patrick Schmidt, Christian M. Seitz
• LB327 · PDF 通过适应性给药策略优化儿科CAR-T细胞患者的氟达拉滨暴露 Optimizing fludarabine exposure in pediatric CAR T-cell patients through an adaptive dosing approach Emma Barlow, Su Han Lum, Geoff Shenton, Denise Bonney, Rachael Hough, Sophie Hambleton, Gareth Veal, Shelby Barnett
• LB328 · PDF 通过适应性给药及制定循证给药指南来优化儿童癌症患者的治疗 Optimising the treatment of childhood cancer patients through adaptive dosing and the generation of evidence-based dosing guidelines Gareth J. Veal, Shelby Barnett, Newcastle Cancer Centre Pharmacology Group
• LB329 · PDF 利用P-selectin靶向纳米药物突破血脑屏障以增强GD2-CAR-T疗法 Overcoming the blood-brain barrier to potentiate GD2-CAR T therapy using P-selectin-targeted nanomedicine Giuseppe Longobardi, Adan Miari, Yulia Liubomirski, Ester Buderovsky, Anat Globerson Levin, Ronit Satchi-Fainaro
• LB330 LB330 TTFields-TTONIC：将肿瘤电场治疗与靶向化疗协同用于肺癌 TTFields-TTONIC: Synergizing tumor treating fields with targeted chemotherapy for lung cancer James Villegas, Sunil Prabhu, Jeffrey Wang, Preshita Desai
• LB331 · PDF 一线（1L）曲妥珠单抗deruxtecan（T-DXd）+ rilvegostomig（rilve）+ 氟嘧啶（FP）治疗HER2阳性（HER2+）胃癌（GC）、胃食管交界处腺癌（GEJA）或食管腺癌（EA）：DESTINY-Gastric03（DG-03）第4部分A组结果 First-line (1L) trastuzumab deruxtecan (T-DXd) + rilvegostomig (rilve) + fluoropyrimidine (FP) in HER2-positive (HER2+) gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) Part 4 arm A results Yelena Y. Janjigian, Hanneke van Laarhoven, Hirokazu Shoji, Lucjan Wyrwicz, Sara Lonardi, Boguslawa Karaszewska, Xinjun Liang, Aitana Calvo Ferrándiz, Mariusz Kwiatkowski, Keun-Wook Lee, Tianshu Liu, Kohei Shitara, Sun Young Rha, Salvatore Siena, Roy Rabbie, Caron Lloyd, Megan Scott, Arthur W. Lambert, Jeeyun Lee
• LB332 LB332 HSK46575，一种强效CYP11A1抑制剂，在治疗去势抵抗性前列腺癌（CRPC）中展示出有前景的单药疗效及与标准治疗（SOC）的协同疗效 HSK46575, a potent CYP11A1 inhibitor, demonstrates promising monotherapy and synergistic efficacy with SOCs for the treatment of castration-resistant prostate cancer (CRPC) Lulin Huang, Meilin Qian, Ju Wang, Yao Li, Zongjun Shi, Guohua Rong, Pangke Yan
• LB334 · PDF 整合AI驱动治疗匹配的患者来源3D肿瘤模型用于靶点发现和个体化治疗 Patient-derived 3D tumor models integrated with AI-driven treatment matching for target discovery and personalized therapy Anshika Katyal, Anne Krinsky, Opal Avramoff, Yulia Liubomirski, Gal Dinstag, Omer Tirosh, Ranit Aharonov, Tuvik Beker, Iris Barshack, Shaked Lev-Ari, Shirly Grynberg, Ronnie Shapira-Frommer, Ronit Satchi-Fainaro
• LB335 · PDF 沉默型KRAS突变改变了细胞对KRAS靶向抑制的敏感性 Silent KRAS mutations confer altered sensitivity to targeted KRAS inhibition Megan A. Satyadi, Rachel Bridgens, Haley Todd, Grace Goodhart, Syed A. Ahmad, Andrew M. Waters
• LB336 · PDF VRN110755：一种用于EGFR突变型NSCLC的新一代非共价EGFR酪氨酸激酶抑制剂 VRN110755: A next-generation non-covalent EGFR tyrosine kinase inhibitor for EGFR-mutated NSCLC Hong-ryul Jung, Tsung-Ying Yang, Byung-Yong Shim, Chia-Chi Lin, Myung-Ju Ahn, Daekwon Kim
• LB337 · PDF Daraxonrasib单药作为转移性胰腺腺癌（mPDAC）患者的一线（1L）治疗 Daraxonrasib monotherapy as first-line (1L) treatment for patients with metastatic pancreatic adenocarcinoma (mPDAC) Eileen M. O'Reilly, Brian Wolpin, Shubham Pant, Joel Randolph Hecht, Jennifer Valerin, Dae Won Kim, Nilofer Azad, Kyaw Aung, Lin Tao, Sumit Kar, Hina Patel, Rashmi Vora, Aparna Hegde, Alexander Spira, Alexander Starodub, Benjamin Herzberg, Ignacio Garrido-Laguna
• LB340 · PDF 基于机制的临床试验匹配揭示卵巢癌中54%的靶点对齐缺口：量化精准可入组的卵巢癌患者 Mechanism-based trial matching reveals a 54% target alignment gap in ovarian cancer: Quantifying the precision-eligible ovarian cancer patients Fahad Kiani

在会议检索中浏览本分会场